Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

HSR26-193: Integrating Print-to-Web Outreach into Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026
Same author

HSR26-193: Integrating Print-to-Web Outreach into Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Quantitative Assessment of Seminoma in the Testicle Among Nonseminomatous Germ Cell Tumor Patients on Operative Difficulty, Morbidity and Pathological Outcomes at Postchemotherapy RPLND.

Clinical genitourinary cancer·2026
Same author

Adverse COVID-19 experiences and physical and psychological outcomes in patients with lung cancer.

Palliative & supportive care·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Aug 12, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.8K

Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

Isamu Tachibana1, Andre Alabd1, Yan Tong2

  • 1Department of Urology, Indiana University School of Medicine, Indianapolis, IN.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|February 2, 2023
PubMed
Summary
This summary is machine-generated.

Primary retroperitoneal lymph node dissection (RPLND) is effective for clinical stage II seminoma, with a 2-year recurrence-free survival of 80.2%. Delayed disease presentation (>12 months) correlated with better surgical outcomes, suggesting surveillance may prevent overtreatment.

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.6K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.9K

Related Experiment Videos

Last Updated: Aug 12, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.8K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.6K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.9K

Area of Science:

  • Urology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Clinical stage (CS) II seminoma is typically treated with chemotherapy or radiotherapy per National Comprehensive Cancer Network guidelines.
  • Primary retroperitoneal lymph node dissection (RPLND) has emerged as a successful first-line therapy for retroperitoneal (RP)-only disease.

Purpose of the Study:

  • To confirm the surgical efficacy of primary RPLND for CS IIA/IIB seminoma.
  • To evaluate recurrence rates after primary RPLND and identify predictive clinical factors.

Main Methods:

  • Retrospective review of 67 patients who underwent primary RPLND for RP-only seminoma between 2014 and 2021.
  • Minimum 6-month follow-up for all patients; exclusion of patients receiving adjuvant chemotherapy from recurrence-free survival (RFS) analysis.

Main Results:

  • The 2-year RFS for RPLND-only patients was 80.2%.
  • Patients with delayed disease presentation (>12 months) had a superior 2-year RFS of 92.2%.
  • Pathologic nodal stage and high-risk factors (tumor size >4 cm, rete testis invasion) did not significantly impact recurrence.

Conclusions:

  • RPLND offers a surgical alternative to chemotherapy or radiotherapy for CS II seminoma, potentially avoiding treatment-related toxicity.
  • Delayed presentation of CS II disease is associated with better surgical outcomes.
  • Careful patient selection and surveillance may help avoid overtreatment in borderline cases; further research is needed.